Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.51 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246005 | 0.93 | TLR2 (0.55) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL13311696 | 0.90 | TLR2 (0.61) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL17747043 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL17747061 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL14877938 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL17747040 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL21908195 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL21326214 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL21326215 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 | |
| SCHEMBL17747033 | 0.90 | TLR2 (0.66) | TLR2KMT2AMDM2SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8454936-B2 | Metal chelators and methods of their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-06-04 | — | — | US | disclosed |
| US-7785565-B2 | Metal chelators and methods of their use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100189645-A1 | METAL CHELATORS AND METHODS OF THEIR USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HOMELAND A (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189645-A1 | METAL CHELATORS AND METHODS OF THEIR USE | SLC30A5, SLC30A7, SLC30A6 | TLR2 3544/4885KMT2A 731/4885MDM2 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.